Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | JAK1 | P23458 | 1/20 | 0.56 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16908653 | 0.84 | JAK2 (0.46) | JAK2JAK1SCN1ASCN8AGAA | |
| SCHEMBL16835473 | 0.80 | JAK2 (0.47) | JAK2JAK1SIGMAR1FUCA1ACHE | |
| SCHEMBL12167511 | 0.80 | ACHE (0.49) | JAK2JAK1GAASIGMAR1FUCA1 | |
| SCHEMBL14302494 | 0.80 | ACHE (0.49) | JAK2JAK1GAASIGMAR1FUCA1 | |
| SCHEMBL5859524 | 0.80 | JAK2 (0.47) | JAK2JAK1GAASIGMAR1FUCA1 | |
| SCHEMBL1190440 | 0.80 | JAK2 (0.47) | JAK2JAK1GAASIGMAR1FUCA1 | |
| SCHEMBL9223591 | 0.80 | JAK2 (0.47) | JAK2JAK1GAASIGMAR1FUCA1 | |
| SCHEMBL19133451 | 0.79 | JAK2 (0.45) | JAK2JAK1SCN1ASCN8AGAA | |
| SCHEMBL19614040 | 0.79 | JAK2 (0.45) | JAK2JAK1SCN1ASCN8AGAA | |
| SCHEMBL19133453 | 0.79 | JAK2 (0.45) | JAK2JAK1SCN1ASCN8AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | JAK2 2904/4885JAK1 3810/4885SCN1A 4597/4885 |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | JAK2 3497/4885JAK1 3462/4885SCN1A 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.